📊 Pipeline Overview

Q1 2026 Board Update

$271.3M

Total Pipeline (Unweighted)

$18.6M

Weighted Pipeline

241

Active Deals

79

Closed Won (All Time)

Active Deals by Stage

Qualification | 5%

177

$181.8M

Qualification

18

$56.1M

Discovery | 10%

32

$19.4M

Proposal | 30%

9

$12.4M

Discovery

1

$1.1M

Contracting | 80%

4

$550K

🔄 Pipeline Movement

Since Last Snapshot

0

New Deals ($0)

0

Stage Changes

0

Closed Won ($0)

0

Closed Lost ($0)

Stage Movements

Deal	From	To	Value
No stage movements detected between snapshots

🏆 Top 10 Deals

By Pipeline Value

StrongHealthyAt-RiskCritical

Company	Deal	Value	Stage	Prob	Last Activity	DM Status	Owner
Leidos	GNAL	$20.5M	Qualification \| 5%	5%	9d ago	⚠️ Needed	Simon Wolpert
U.S. Department of Veterans Affairs	VA (EHR Modernization Integration Office)	$18.2M	Qualification	10%	649d ago	⚠️ Needed	Simon Wolpert
Orion Health Ltd	Malaffi Super App	$8.0M	Qualification	10%	1d ago	⚠️ Needed	Simon Wolpert
Alberta Health Services	Alberta Health Services - Patient Portal (via Orion & Telus/IBM)	$7.8M	Qualification \| 5%	5%	93d ago	⚠️ Needed	Simon Wolpert
OBEIKAN INVESTMENT GROUP	Saudi MoH Sehhaty App	$7.1M	Qualification	10%	221d ago	⚠️ Needed	Daniel Nathrath
Ontraiohealth	Ontario Upsell - FTI + Concierge	$7.0M	Qualification	10%	261d ago	⚠️ Needed	Simon Wolpert
Blue Shield of California	Blue Shield of California	$6.5M	Proposal \| 30%	30%	9d ago	⚠️ Needed	Simon Wolpert
AstraZeneca	AstraZeneca \| aHUS, PNH, HPP \| UAE - Phase 2	$6.0M	Qualification \| 5%	1%	16d ago	✅ Identified	Eran Desheh
AstraZeneca	AstraZeneca \| ATTR-CM \| UAE - Phase 2	$6.0M	Qualification \| 5%	1%	16d ago	✅ Identified	Eran Desheh
Biogen	Biogen \| Friedreichs Ataxia \| Global - Phase 2	$6.0M	Qualification \| 5%	5%	6d ago	Unknown	Eran Desheh

📞 Sales Activity

Call Performance

564

Calls Graded

2.15/5

Avg Call Score

2.45/5

Objection Handling

2.74/5

Next Steps / Commitment

Objection Handling Score

Commitment Fulfillment

Key Insights

See weekly scorecard for detailed activity breakdown

⚔️ Competitive Landscape

Threat Assessment

Threat Matrix

Veeva Systems

Threat: High

Dominant in life sciences CRM; limited patient-finding

Komodo Health

Threat: Medium

Claims patient journey analytics

IQVIA

Threat: Medium

Broad data assets; less AI-native

Tempus AI

Threat: Low

Oncology focused; different segment

Key Competitive Moves

🔍 No competitive warroom data available — update ~/clawd/competitive/warroom.json

Ada Differentiation

FDA-cleared AI symptom assessment engine
300M+ assessments powering patient-finding accuracy
Full patient journey: awareness → diagnosis → treatment
Regulatory-grade evidence generation

🎯 Targets & Forecast

2026 Revenue Target

$30.0M

2026 Target

$121.1M

Signed Revenue

$18.6M

Projected Close

$0

Gap to Target

Progress to $30M Target

$0 $121.1M signed (403.6%) $30.0M

Forecast Breakdown

■ Signed ■ Projected ■ Gap: $0

📌 Based on weighted pipeline (no prediction model available)